{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Emerging Oral Antiviral Therapies for COVID-19, Early Evidence for the Clinical Nurse Specialist
Activity Steps
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Learning Objectives
After completing this continuing education activity you will be able to:
- Select indications for the use of molnupiravir and/or PF-07321332-ritonavir.
- Specify issues related to the administration of PF-07321332-ritonavir andmolnupiravir.
- Identify a country that has authorized the use of molnupiravir.
- Explain the actions of PF-07321332-ritonavir.
Learning Outcomes
75% of participants will demonstrate knowledge of PF-07321332-ritonavir and molnupiravir by achieving a minimum score of 70% on the outcomes-based posttest.Disclosures
The drugs presented in this article have not received FDA approval for use in the US. The author and planners have disclosed no potential conflicts of interest, financial or otherwise.
Price:
$17.95
Credits:
- ANCC 1.5 CH / 1.5 APH
- DC - BON 1.5 CH
- FL - BON 1.5 CH
- GA - BON 1.5 CH
Lippincott Professional Development is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, and Georgia Board of Nursing, #50-1223.
Awarded Advanced Pharmacology Hours
Awarded Advanced Pharmacology Hours
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Test Code: CNS0322
Published: Mar/Apr 2022
Expires: 3/7/2025
Required Passing Score: 8/10 (80%)
Specialties:
Advanced Practice Nursing,
Infectious Diseases
Topics:
Antivirals
,
COVID-19